Sunday, July 05, 2020 9:19:55 AM
"Nader says no R/S".... and of course the diehards take him at his word.
Trust me there will be several. Whether it's tomorrow or months from now.
"We had multiple good news events and no R/S".
Are you saying that because theres been news events in the past that no R/S then means no R/S ever??? You gotta be kiddin me. They'll do it they think it'll work.
In case financing- "In case" what? They need it? We'll they need it now.They're broke.
Hostile takeover prevention purpose- LOL. I don't believe it .
Betcha they'll be selling into the market right now. After all, they're currently technically bankrupt and in dire need of cash. Doesn't appear anyone is interested in them.
Shareholders would riot over a R/S. Not if they sell it right to the gullible shareholders.
Yes the BOD would have to approve. they're rubber stamps and carry the CEO's wated. So they'd approve.
Uplisting Problems- OK so get the uplisting 1st. Aren't you expecting that is was to occur already......... but for some strange reason has not
DEBUNKED YOURE ARGUMENT IS WEAK.
Trust me there will be several. Whether it's tomorrow or months from now.
"We had multiple good news events and no R/S".
Are you saying that because theres been news events in the past that no R/S then means no R/S ever??? You gotta be kiddin me. They'll do it they think it'll work.
In case financing- "In case" what? They need it? We'll they need it now.They're broke.
Hostile takeover prevention purpose- LOL. I don't believe it .
Betcha they'll be selling into the market right now. After all, they're currently technically bankrupt and in dire need of cash. Doesn't appear anyone is interested in them.
Shareholders would riot over a R/S. Not if they sell it right to the gullible shareholders.
Yes the BOD would have to approve. they're rubber stamps and carry the CEO's wated. So they'd approve.
Uplisting Problems- OK so get the uplisting 1st. Aren't you expecting that is was to occur already......... but for some strange reason has not
DEBUNKED YOURE ARGUMENT IS WEAK.
Recent CYDY News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/02/2025 10:15:21 PM
